Drugs / MSDC-0602K
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT02784444 Comparator | Sep 2016 → Jun 2019 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Cirius Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03970031 Comparator | Jun 2022 → Sep 2024 | NAFLD1, metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | Cirius Therapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSDC-0602K | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03970031 ↗ |
| Route | Oral | “MSDC-0602K or placebo given orally once daily” NCT02784444 ↗ |